Emergent BioSolutions | EBS - Capital Ordinário





Capital Ordinário Alterar Data
Acadia Pharmaceuticals USD 171.09M 1.9M 2026-03
Akebia Therapeutics USD 265.42M 199K 2025-12
ALKERMES USD 167.54M 1.08M 2026-06
Alnylam Pharmaceuticals USD 133.73M 290K 2026-06
Amarin USD 20.81M 13K 2025-12
ANI Pharmaceuticals USD 22.49M 760K 2025-12
BioMarin Pharmaceutical USD 193.54M 267K 2026-06
Coherus Biosciences USD 121.16M 4.92M 2025-12
Emergent BioSolutions USD 100K 0 2023-06
Exelixis USD 248.88M 4.82M 2026-06
Glaxosmithkline GBP 4.05B 20.6M 2026-03
Heron Therapeutics USD 188.31M 4.99M 2025-12
Ionis Pharmaceuticals USD 165.64M 265K 2026-06
Ironwood Pharmaceuticals USD 160K 0 2024-12
Lexicon Pharmaceuticals USD 363.47M 67K 2025-12
Lonza CHF 68.64M 0 2025-12
Merck USD 2.47B 4.93M 2026-03
Moderna USD 391M 2M 2025-09
Myriad Genetics USD 93.5M 400K 2025-12
Nektar Therapeutics USD 29.47M 9.09M 2026-03
Neurocrine Biosciences USD 100.55M 50K 2026-06
Pacira USD 39.82M 512K 2026-06
Pfizer USD 5.7B 0 2026-06
PTC Therapeutics USD 82.88M 1.41M 2026-03
Sanofi EUR 1.21B 8.25M 2026-03
Sarepta Therapeutics USD 105.62M 53K 2026-06
United Therapeutics USD 42.68M 521K 2026-06
Vanda Pharmaceuticals USD 58K 0 2024-12